The company, currently valued at $358.24M, closed the last trade at $2.75 per share which meant it gained $0.15 on … Citius Pharmaceuticals, Inc. Common Stock, also called Citius Pharmaceuticals, is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. Citius Pharmaceuticals 's earnings in 2021 is -$21,070,087.On average, 2 Wall Street analysts forecast CTXR's earnings for 2021 to be $-33,191,117, with the lowest CTXR earnings forecast at $-35,223,226, and the highest CTXR earnings forecast at $-31,159,008. Citius Subsidiary: NoveCite is a subsidiary of Citius Pharmaceuticals working on a new age cellular therapy drug. The 1-year high price for the company’s stock is recorded $2.90 on 02/22/21, with the lowest value was $1.00 for the same time period, recorded on 01/04/21. 2. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. The Company develops and commercializes previously approved therapeutic products. By using . Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial - DMC Meeting on June 29. Citius Pharmaceuticals Could Offer Relief in an $80 Million Hemorrhoids Market. Catalyst . ABOUT: Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for growing markets.Citius products offer new and expanded indications for previously-approved pharmaceutical products as a means to achieve leading market positioning. View recent trades and share price information for Citius Pharmaceuticals Inc USD0.001 Citius Pharmaceuticals, Inc (CTXR) is a leading biotechnology business based in the US. The latest price was $2.6 (25 minute delay). The Company concentrates on adjunctive cancer … Citius Pharmaceuticals, Inc. FORM 10-K September 30, 2020 TABLE OF CONTENTS Page PART I Item 1. Business 1 Item 1A. Press Release reported on 03/04/21 that Citius Pharmaceuticals to Feature CTXR 2.57 0.02 (0.78%) Citius products offer new and expanded indications for previously approved pharmaceutical products as a means to achieve leading market position or market exclusivity. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. Citius Pharmaceuticals Inc. (NASDAQ:CTXR) went up by 1.13% from its latest closing price compared to the recent 1-year high of $2.90. About Citius Pharmaceuticals, Inc. Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a … It primarily focuses on developing anti-infective, cancer care, prescription, and mesen... Show more. Estimates by analysts give the company expected earnings per share (EPS) of -$0.05, with the EPS growth for the year raised at -$0.3 for 2021 and $0.31 for next year. Citius Pharmaceuticals, Inc. Reports Second Fiscal Quarter 2021 Financial Results and Provides General Business Update Small Update Raised gross proceeds of $96.5 million from financing activities during the quarter providing financial runway into 2023 $2.28. Forward Looking Statements . The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging … Get the latest Citius Pharmaceuticals Inc (CTXR) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Provided by PR Newswire Jun 16, 2021 2:50 PM UTC The company is engaged in the development and commercialization of anti … Citius Pharmaceuticals' stock is trading up $0.10 today. In March 2016, Citius announced that it has a worldwide license for Mino-Lok. Vanguard Group, Inc. (The) is the largest shareholder of the company, while 44 institutions own stock in it. Citius Pharmaceuticals, Inc. (CTXR) projections and forecasts. It primarily focuses on … (16) However, that could soon change with Citius’ halobetasol and lidocaine formulations. About Citius Pharmaceuticals, Inc. Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first … Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for large and growing markets. About Citius Pharmaceuticals, Inc. Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. Vanguard Group Inc had filed a previous 13F-HR on 2021-02-12 disclosing 755,119 shares of Citius Pharmaceuticals Inc at a value of $770,000 USD. Citius Pharmaceuticals, Inc. earnings are expected to increase by 42% in 2021, but the outlook is negative 0% per year for the next five years. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. Citius Pharmaceuticals Inc. has a market cap of $338.70 million. Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, announced that it will present at the H.C. Wainwright Global Life Sciences Conference, to be held virtually on March 9-10, 2021. Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for large and growing markets. Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 20%. Citius Pharmaceuticals, Inc., formerly Trail One, Inc., is a pharmaceutical company engaged in developing and commercializing therapeutic products. Risk Factors 18 Item 1B Unresolved Staff Comments 41 Item 2. About Citius Pharmaceuticals, Inc. Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. The company is engaged in the development and commercialization of anti-infective products, adjunctive cancer care, and unique prescription products. Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. To short Citius Pharmaceuticals stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging … About Citius Pharmaceuticals, Inc. Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. About Citius Pharmaceuticals, Inc. Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. Citius Pharmaceuticals didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. Citius Pharmaceuticals overlap studies tool provides the execution environment for running the SIMPLE MOVING AVERAGE study and other technical functions against Citius Pharmaceuticals. "On June 7, 2021, Citius Pharmaceuticals, Inc. issued a press release announcing that it has been added to the Russell 2000® Index at the conclusion of the Russell US Indexes annual reconstitution, effective at the opening of the U.S. equity markets on June 28, 2021. Citius Pharmaceuticals Inc. insiders own 9.09% of total outstanding shares while institutional holders control 13.25%, with the float percentage being 14.57%. Citius Pharmaceuticals Inc. had a pretty favorable run when it comes to the market performance. The latest Citius Pharmaceuticals Inc USD0.001 share price. Citius Pharmaceuticals Inc stock price down 1.72% on Friday (Updated on May 28, 2021) The Citius Pharmaceuticals Inc stock price fell by -1.72% on the last day (Friday, 28th May 2021) from $2.32 to $2.28. Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)’s Biggest Investors. Citius Pharmaceuticals (NASDAQ: CTXR) is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for large and growing markets. About Citius Pharmaceuticals, Inc. Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. Get the latest Citius Pharmaceuticals detailed stock quotes, stock trade data, stock price info, and performance analysis, including Citius investment advice, charts, stats and more. Citius Pharmaceuticals Inc is a specialty pharmaceutical company. Press Release reported on 04/30/21 that Thinking about buying stock in No Data is currently not available. Company Analysis and Financial Data Status. -0.04 (-1.72%) DATA AS OF May 28, … Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. Citius Pharmaceuticals, Inc. Common Stock, also called Citius Pharmaceuticals, is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. Citius Pharmaceuticals Inc is a specialty pharmaceutical company. The … Citius Pharmaceuticals Inc is a specialty pharmaceutical company. Properties 41 Item 3. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. Citius Pharmaceuticals is listed on the NASDAQ and employs 10 staff. Citius Pharmaceuticals Inc. (NASDAQ:CTXR) has a beta value of 1.58 and has seen 7.61 million shares traded in the last trading session. Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a … About Citius Pharmaceuticals, Inc. Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. It primarily focuses on … Citius Pharmaceuticals (NASDAQ: CTXR) is a specialty pharmaceutical company dedicated to the development and commercialization of important new drug products for growing markets. Citius Pharmaceuticals obtained a worldwide license to the patented technology (with the exception of South America) in May 2014. It opened the day at $2.55 after a previous close of $2.5. Citius is currently advancing two proprietary product candidates, Mino-Lok product and a Hydrocortisone-Lidocaine formulation. We would like to show you a description here but the site won’t allow us. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. About Citius Pharmaceuticals, Inc. Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. Nasdaq 100. Citius Pharmaceuticals, Inc. 11 Commerce Drive, 1st Floor Cranford, NJ 07016 NOTICE OF SPECIAL MEETING OF STOCKHOLDERS To Be Held On May 24, 2021 Dear Stockholder: You are cordially invited to attend the Special Meeting of Stockholders of Citius Pharmaceuticals, Inc. About Citius Pharmaceuticals, Inc. Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. Hemorrhoids are an uncomfortable and often recurring condition. The stock's lowest day price was 2.48. About Citius Pharmaceuticals, Inc. Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a … Citius Pharmaceuticals Inc. has a market cap of $338.70 million. About Citius Pharmaceuticals, Inc. Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first … Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial - DMC Meeting on June 29. Estimates by analysts give the company expected earnings per share (EPS) of -$0.05, with the EPS growth for the year raised at -$0.3 for 2021 and $0.31 for next year. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. Citius Pharmaceuticals, Inc. insiders own 9.14% of total outstanding shares while institutional holders control 6.7%, with the float percentage being 7.37%. The stock currently trades just under two bucks a share and sports an … Citius Pharmaceuticals Inc () Stock Market info Recommendations: Buy or sell Citius Pharmaceuticals stock? Since early 2020, Citius Pharmaceuticals has been in a strong uptrend. Citius Pharmaceuticals Inc. (CTXR) full year performance was 198.88%. Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. (RTTNews) - Shares of Citius Pharmaceuticals Inc. (CTXR) are up over 20% in pre-market trading Monday as the company looks ahead to a couple … It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. Posted by 2 days ago. Citius Pharmaceuticals is a small ' Tier 4 ' developmental firm based in New Jersey. Citius Pharmaceuticals (NASDAQ: CTXR) is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for large and growing markets. Vanguard Group, Inc. (The) is the largest shareholder of the company, while 30 institutions own stock in it. The company is engaged in the development and commercialization of anti … Legal Proceedings 41 Item 4. Citius Pharmaceuticals serves customers in … Close. Citius Pharmaceuticals (NASDAQ:CTXR) Looks Technically Strong. Shockingly, there are no FDA-approved prescription products for hemorrhoids at the moment. For example, Citius Pharmaceuticals (NASDAQ:CTXR) shareholders have done very well over the last year, with the … About Citius Pharmaceuticals, Inc. Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first … On February 17, Citius Pharmaceuticals announced that it has entered into definitive agreements with certain healthcare-focused and institutional investors for the purchase of an aggregate of 50,830,566 shares of its common stock and accompanying warrants to purchase up to an aggregate of 25,415,283 shares of its common stock at a purchase price of $1.505 per share and accompanying … During the day the price has varied from a low of $2.48 to a high of $2.6. Citius Pharmaceuticals Inc. (NASDAQ:CTXR) went up by 4.27% from its latest closing price compared to the recent 1-year high of $2.90. About Citius Pharmaceuticals, Inc. Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. Citius Pharmaceuticals, Inc. is headquartered in Cranford, New Jersey. Considering analysts have assigned the stock a price target range of $4-$8 as the low and high respectively, we find the trailing 12-month average consensus price target to be $6. About Citius Pharmaceuticals Inc Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. Citius Pharmaceuticals stock price prediction is an act of determining the future value of Citius Pharmaceuticals shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation.The successful prediction of Citius Pharmaceuticals stock future price could yield a significant profit. Data Last Updated (UTC time) Company Analysis: … Citius Pharmaceuticals Inc. NASDAQ Updated Jun 9, 2021 5:44 AM. Citius Pharmaceuticals stock price trend is the prevailing direction of the price over some defined period of time. 356. Our products offer new and expanded indications for previously approved pharmaceutical products as a means to achieve leading market positioning. For more information, please visit www.citiuspharma.com. Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, announced that it will present at the H.C. Wainwright Global Life Sciences Conference, to be held virtually on March 9 … The company’s stock price has collected -11.82% of loss in the last five trading sessions. It engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care and prescription products. Citius Pharmaceuticals, Inc. Common Stock (CTXR) Nasdaq Listed. Citius Pharmaceuticals stock is selling at 2.60 as of the 14th of June 2021; that is 1.96 percent increase since the beginning of the trading day. CTXR Citius Pharmaceuticals Inc. — Stock Price and Discussion | Stocktwits. The Company develops and commercializes previously approved therapeutic products. Company Name: Citius Pharmaceuticals Inc., Stock Symbol: CTXR, Total Posts: 445, Last Post: 6/8/2021 7:42:47 PM 2021-05-14 - Vanguard Group Inc has filed a 13F-HR form disclosing ownership of 5,066,235 shares of Citius Pharmaceuticals Inc (US:CTXR) with total holdings valued at $9,018,000 USD as of 2021-03-31.
citius pharmaceuticals
The company, currently valued at $358.24M, closed the last trade at $2.75 per share which meant it gained $0.15 on … Citius Pharmaceuticals, Inc. Common Stock, also called Citius Pharmaceuticals, is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. Citius Pharmaceuticals 's earnings in 2021 is -$21,070,087.On average, 2 Wall Street analysts forecast CTXR's earnings for 2021 to be $-33,191,117, with the lowest CTXR earnings forecast at $-35,223,226, and the highest CTXR earnings forecast at $-31,159,008. Citius Subsidiary: NoveCite is a subsidiary of Citius Pharmaceuticals working on a new age cellular therapy drug. The 1-year high price for the company’s stock is recorded $2.90 on 02/22/21, with the lowest value was $1.00 for the same time period, recorded on 01/04/21. 2. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. The Company develops and commercializes previously approved therapeutic products. By using . Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial - DMC Meeting on June 29. Citius Pharmaceuticals Could Offer Relief in an $80 Million Hemorrhoids Market. Catalyst . ABOUT: Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for growing markets.Citius products offer new and expanded indications for previously-approved pharmaceutical products as a means to achieve leading market positioning. View recent trades and share price information for Citius Pharmaceuticals Inc USD0.001 Citius Pharmaceuticals, Inc (CTXR) is a leading biotechnology business based in the US. The latest price was $2.6 (25 minute delay). The Company concentrates on adjunctive cancer … Citius Pharmaceuticals, Inc. FORM 10-K September 30, 2020 TABLE OF CONTENTS Page PART I Item 1. Business 1 Item 1A. Press Release reported on 03/04/21 that Citius Pharmaceuticals to Feature CTXR 2.57 0.02 (0.78%) Citius products offer new and expanded indications for previously approved pharmaceutical products as a means to achieve leading market position or market exclusivity. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. Citius Pharmaceuticals Inc. (NASDAQ:CTXR) went up by 1.13% from its latest closing price compared to the recent 1-year high of $2.90. About Citius Pharmaceuticals, Inc. Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a … It primarily focuses on developing anti-infective, cancer care, prescription, and mesen... Show more. Estimates by analysts give the company expected earnings per share (EPS) of -$0.05, with the EPS growth for the year raised at -$0.3 for 2021 and $0.31 for next year. Citius Pharmaceuticals, Inc. Reports Second Fiscal Quarter 2021 Financial Results and Provides General Business Update Small Update Raised gross proceeds of $96.5 million from financing activities during the quarter providing financial runway into 2023 $2.28. Forward Looking Statements . The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging … Get the latest Citius Pharmaceuticals Inc (CTXR) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Provided by PR Newswire Jun 16, 2021 2:50 PM UTC The company is engaged in the development and commercialization of anti … Citius Pharmaceuticals' stock is trading up $0.10 today. In March 2016, Citius announced that it has a worldwide license for Mino-Lok. Vanguard Group, Inc. (The) is the largest shareholder of the company, while 44 institutions own stock in it. Citius Pharmaceuticals, Inc. (CTXR) projections and forecasts. It primarily focuses on … (16) However, that could soon change with Citius’ halobetasol and lidocaine formulations. About Citius Pharmaceuticals, Inc. Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first … Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for large and growing markets. About Citius Pharmaceuticals, Inc. Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. Vanguard Group Inc had filed a previous 13F-HR on 2021-02-12 disclosing 755,119 shares of Citius Pharmaceuticals Inc at a value of $770,000 USD. Citius Pharmaceuticals, Inc. earnings are expected to increase by 42% in 2021, but the outlook is negative 0% per year for the next five years. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. Citius Pharmaceuticals Inc. has a market cap of $338.70 million. Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, announced that it will present at the H.C. Wainwright Global Life Sciences Conference, to be held virtually on March 9-10, 2021. Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for large and growing markets. Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 20%. Citius Pharmaceuticals, Inc., formerly Trail One, Inc., is a pharmaceutical company engaged in developing and commercializing therapeutic products. Risk Factors 18 Item 1B Unresolved Staff Comments 41 Item 2. About Citius Pharmaceuticals, Inc. Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. The company is engaged in the development and commercialization of anti-infective products, adjunctive cancer care, and unique prescription products. Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. To short Citius Pharmaceuticals stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging … About Citius Pharmaceuticals, Inc. Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. About Citius Pharmaceuticals, Inc. Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. Citius Pharmaceuticals didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. Citius Pharmaceuticals overlap studies tool provides the execution environment for running the SIMPLE MOVING AVERAGE study and other technical functions against Citius Pharmaceuticals. "On June 7, 2021, Citius Pharmaceuticals, Inc. issued a press release announcing that it has been added to the Russell 2000® Index at the conclusion of the Russell US Indexes annual reconstitution, effective at the opening of the U.S. equity markets on June 28, 2021. Citius Pharmaceuticals Inc. insiders own 9.09% of total outstanding shares while institutional holders control 13.25%, with the float percentage being 14.57%. Citius Pharmaceuticals Inc. had a pretty favorable run when it comes to the market performance. The latest Citius Pharmaceuticals Inc USD0.001 share price. Citius Pharmaceuticals Inc stock price down 1.72% on Friday (Updated on May 28, 2021) The Citius Pharmaceuticals Inc stock price fell by -1.72% on the last day (Friday, 28th May 2021) from $2.32 to $2.28. Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)’s Biggest Investors. Citius Pharmaceuticals (NASDAQ: CTXR) is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for large and growing markets. About Citius Pharmaceuticals, Inc. Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. Get the latest Citius Pharmaceuticals detailed stock quotes, stock trade data, stock price info, and performance analysis, including Citius investment advice, charts, stats and more. Citius Pharmaceuticals Inc is a specialty pharmaceutical company. Press Release reported on 04/30/21 that Thinking about buying stock in No Data is currently not available. Company Analysis and Financial Data Status. -0.04 (-1.72%) DATA AS OF May 28, … Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. Citius Pharmaceuticals, Inc. Common Stock, also called Citius Pharmaceuticals, is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. Citius Pharmaceuticals Inc is a specialty pharmaceutical company. The … Citius Pharmaceuticals Inc is a specialty pharmaceutical company. Properties 41 Item 3. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. Citius Pharmaceuticals is listed on the NASDAQ and employs 10 staff. Citius Pharmaceuticals Inc. (NASDAQ:CTXR) has a beta value of 1.58 and has seen 7.61 million shares traded in the last trading session. Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a … About Citius Pharmaceuticals, Inc. Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. It primarily focuses on … Citius Pharmaceuticals (NASDAQ: CTXR) is a specialty pharmaceutical company dedicated to the development and commercialization of important new drug products for growing markets. Citius Pharmaceuticals obtained a worldwide license to the patented technology (with the exception of South America) in May 2014. It opened the day at $2.55 after a previous close of $2.5. Citius is currently advancing two proprietary product candidates, Mino-Lok product and a Hydrocortisone-Lidocaine formulation. We would like to show you a description here but the site won’t allow us. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. About Citius Pharmaceuticals, Inc. Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. Nasdaq 100. Citius Pharmaceuticals, Inc. 11 Commerce Drive, 1st Floor Cranford, NJ 07016 NOTICE OF SPECIAL MEETING OF STOCKHOLDERS To Be Held On May 24, 2021 Dear Stockholder: You are cordially invited to attend the Special Meeting of Stockholders of Citius Pharmaceuticals, Inc. About Citius Pharmaceuticals, Inc. Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. Hemorrhoids are an uncomfortable and often recurring condition. The stock's lowest day price was 2.48. About Citius Pharmaceuticals, Inc. Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a … Citius Pharmaceuticals Inc. has a market cap of $338.70 million. About Citius Pharmaceuticals, Inc. Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first … Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial - DMC Meeting on June 29. Estimates by analysts give the company expected earnings per share (EPS) of -$0.05, with the EPS growth for the year raised at -$0.3 for 2021 and $0.31 for next year. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. Citius Pharmaceuticals, Inc. insiders own 9.14% of total outstanding shares while institutional holders control 6.7%, with the float percentage being 7.37%. The stock currently trades just under two bucks a share and sports an … Citius Pharmaceuticals Inc () Stock Market info Recommendations: Buy or sell Citius Pharmaceuticals stock? Since early 2020, Citius Pharmaceuticals has been in a strong uptrend. Citius Pharmaceuticals Inc. (CTXR) full year performance was 198.88%. Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. (RTTNews) - Shares of Citius Pharmaceuticals Inc. (CTXR) are up over 20% in pre-market trading Monday as the company looks ahead to a couple … It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. Posted by 2 days ago. Citius Pharmaceuticals is a small ' Tier 4 ' developmental firm based in New Jersey. Citius Pharmaceuticals (NASDAQ: CTXR) is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for large and growing markets. Vanguard Group, Inc. (The) is the largest shareholder of the company, while 30 institutions own stock in it. The company is engaged in the development and commercialization of anti … Legal Proceedings 41 Item 4. Citius Pharmaceuticals serves customers in … Close. Citius Pharmaceuticals (NASDAQ:CTXR) Looks Technically Strong. Shockingly, there are no FDA-approved prescription products for hemorrhoids at the moment. For example, Citius Pharmaceuticals (NASDAQ:CTXR) shareholders have done very well over the last year, with the … About Citius Pharmaceuticals, Inc. Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first … On February 17, Citius Pharmaceuticals announced that it has entered into definitive agreements with certain healthcare-focused and institutional investors for the purchase of an aggregate of 50,830,566 shares of its common stock and accompanying warrants to purchase up to an aggregate of 25,415,283 shares of its common stock at a purchase price of $1.505 per share and accompanying … During the day the price has varied from a low of $2.48 to a high of $2.6. Citius Pharmaceuticals Inc. (NASDAQ:CTXR) went up by 4.27% from its latest closing price compared to the recent 1-year high of $2.90. About Citius Pharmaceuticals, Inc. Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. Citius Pharmaceuticals, Inc. is headquartered in Cranford, New Jersey. Considering analysts have assigned the stock a price target range of $4-$8 as the low and high respectively, we find the trailing 12-month average consensus price target to be $6. About Citius Pharmaceuticals Inc Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. Citius Pharmaceuticals stock price prediction is an act of determining the future value of Citius Pharmaceuticals shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation.The successful prediction of Citius Pharmaceuticals stock future price could yield a significant profit. Data Last Updated (UTC time) Company Analysis: … Citius Pharmaceuticals Inc. NASDAQ Updated Jun 9, 2021 5:44 AM. Citius Pharmaceuticals stock price trend is the prevailing direction of the price over some defined period of time. 356. Our products offer new and expanded indications for previously approved pharmaceutical products as a means to achieve leading market positioning. For more information, please visit www.citiuspharma.com. Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, announced that it will present at the H.C. Wainwright Global Life Sciences Conference, to be held virtually on March 9 … The company’s stock price has collected -11.82% of loss in the last five trading sessions. It engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care and prescription products. Citius Pharmaceuticals, Inc. Common Stock (CTXR) Nasdaq Listed. Citius Pharmaceuticals stock is selling at 2.60 as of the 14th of June 2021; that is 1.96 percent increase since the beginning of the trading day. CTXR Citius Pharmaceuticals Inc. — Stock Price and Discussion | Stocktwits. The Company develops and commercializes previously approved therapeutic products. Company Name: Citius Pharmaceuticals Inc., Stock Symbol: CTXR, Total Posts: 445, Last Post: 6/8/2021 7:42:47 PM 2021-05-14 - Vanguard Group Inc has filed a 13F-HR form disclosing ownership of 5,066,235 shares of Citius Pharmaceuticals Inc (US:CTXR) with total holdings valued at $9,018,000 USD as of 2021-03-31.
Katherine Murphy Obituary, Tasting Menu Buckinghamshire, Trackhouse Racing Jobs, Approbation Definition, Kagoshima Weather Year Round, Nac Breda Vs De Graafschap Forebet, Birch Benders Keto Products,